Completed PHASE2 INTERVENTIONAL 3-arm NCT02001688

Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation

Phase II, Double-Blind, Placebo-Controlled Study to Explore the ELF and Plasma Concentration as Well as Safety of Inhaled Alpha-1 Antitrypsin in Alpha-1 Antitrypsin Deficiency Subjects

Sponsor: Kamada, Ltd.

Conditions Alpha-1 Antitrypsin Deficiency

Interventions Kamada-AAT for Inhalation, 160mg Kamada-AAT for Inhalation, 80mg Placebo

Updated 7 times since 2017 Last updated: Dec 31, 2019 Started: Apr 30, 2014 Primary completion: Feb 29, 2016 Completion: May 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Alpha-1 Antitrypsin Deficiency, this trial is completed. The trial is conducted by Kamada, Ltd. and has accumulated 7 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Feb 2020 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Feb 2020 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Apr 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kamada, Ltd.

Data source: Kamada, Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Gainesville, United States
• Tyler, United States